Browse a selection of key resources and publications about our pipeline.

CLN-978, a CD19xCD3 T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases (2025 ACR)

Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR exon 20 insertion (ex20ins)/Other Uncommon Mutations (2025 ESMO)

Balancing the Immune System With T Cell Engagers

CD19: A Key Target in Treating Autoimmune Diseases

BCMA: A Promising Target in Autoimmune Diseases

2025 WCLC REZILIENT2

2025 WCLC REZILIENT1

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 JCO)

Efficacy of Zipalertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutations Who Received Prior Platinum-Based Chemotherapy With or Without Amivantamab (2025 ASCO)

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study of CLN-049 for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease (2024 ASH)